Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PD173074 |
Trade Name | |
Synonyms | PD-173074|PD 173074 |
Drug Descriptions |
PD173074 is an ATP-competitive inhibitor of FGFR1, FGFR3, FGFR4, and KDR (VEGFR2), which may reduce proliferation and induce apoptosis in cancer cells (PMID: 9774334, PMID: 24126887, PMID: 14715624, PMID: 30544798). |
DrugClasses | FGFR1 Inhibitor 28 FGFR3 Inhibitor 19 FGFR4 Inhibitor 9 VEGFR2 Inhibitor 37 |
CAS Registry Number | 219580-11-7 |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABT-737 + PD173074 | ABT-737 PD173074 | 3 | 0 |
Dasatinib + PD173074 | Dasatinib PD173074 | 1 | 0 |
Fulvestrant + Palbociclib + PD173074 | Fulvestrant PD173074 Palbociclib | 0 | 0 |
Fulvestrant + PD173074 | Fulvestrant PD173074 | 0 | 0 |
Gefitinib + PD173074 | Gefitinib PD173074 | 0 | 0 |
Palbociclib + PD173074 | PD173074 Palbociclib | 0 | 0 |
PD173074 | PD173074 | 32 | 0 |
PD173074 + Quizartinib | PD173074 Quizartinib | 0 | 0 |
PD173074 + Trabectedin | PD173074 Trabectedin | 1 | 0 |